NxThera puts a bow on a $20 million Series C round for its Rezūm prostate device.
NxThera said it closed a $20 million Series C round that topped its initial $18 million target.
Maple Grove, Minn.-based NxThera won CE Mark approval in the European Union last August for its Rezūm prostate device, which uses steam to reduce the size of the prostate to relieve urinary symptoms from benign prostate hyperplasia.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/OWDU0p
Cap comentari:
Publica un comentari a l'entrada